Inhibition of MIF Bioactivity by Rational Design of Pharmacological Inhibitors of MIF Tautomerase Activity
Angeles Dios, Yousef Al‐Abed(Feinstein Institute for Medical Research), Jodi B. Lubetsky(Yale University), Hong Liao(Kunming University of Science and Technology), KerryAnn O'Connor(Yale University), Elias Lolis(Yale University), Bayan Aljabari, Christine N. Metz(Northwell Health), Peter D. Senter(Seagen (United States)), Kirk R. Manogue, Robert A. Mitchell(University of Louisville), Richard Bucala(Yale University), David J.E. Callaway(Yale University)
Cited by 125
Related Papers
Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate
|Clinical Cancer Research|2004|1.2k
Development of potent monoclonal antibody auristatin conjugates for cancer therapy
|Nature Biotechnology|2003|1.2k
MIF Signal Transduction Initiated by Binding to CD74
|The Journal of Experimental Medicine|2003|1.1k
Arming antibodies: prospects and challenges for immunoconjugates
|Nature Biotechnology|2005|1k